Skip to main content

In-Depth Analysis on Opioid Use Disorder Market Size | USD 6.14 Billion by 2030

As per the report by Fortune Business Insights, the global Opioid Use Disorder Market size is projected to reach USD 6.14 billion in 2030, at a CAGR of 9.1% during the forecast period, 2023-2030

Pune, India, June 06, 2023 (GLOBE NEWSWIRE) — The global Opioid Use Disorder (OUD) market size was valued at USD 3.10 billion in 2022. The market is projected to grow from USD 3.35 billion in 2023 to USD 6.14 billion by 2030, exhibiting a CAGR of 9.1% during the forecast period. The rise is due to the increasing formulation of regulatory policies for addressing the condition. The treatment constitutes three drug classes – buprenorphine, methadone, and naltrexone.

This information is presented by Fortune Business Insights, in its report titled, “Opioid Use Disorder (OUD) Market, 2023-2030.”


Request a Free Sample Copy of the Research Report:

https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/opioid-use-disorder-oud-market-102674


Key Industry Development:

March 2022: Collegium Pharmaceutical, Inc. declared that it has successfully accomplished the acquisition of BioDelivery Sciences International Inc.

Key Takeaways:

  • In order to create a clinical trial for the creation of a Lidocaine patch for OUD treatment, WellSpan Health teamed up with York Opioid Collaboration in 2019.
  • In 2021, the CDC reported that approximately 2.7 million individuals aged 12 or older in the United States disclosed having OUD.
  • The market is divided into three categories based on drug class: methadone, buprenorphine, and naltrexone
  • The hospital pharmacies segment is expected to dominate due to its significant reliance on this channel

Discover the Leading Players Featured in the Report:

Indivior PLC (U.S.), Alkermes (Ireland) , Orexo AB (Sweden), Titan Pharmaceuticals, Inc. (U.S.)  ,Mallinckrodt Pharmaceuticals (U.K) , BioDelivery Sciences International Inc. (U.S. , Viatris Inc. (Mylan N.V.) (U.S.), Hikma Pharmaceuticals PLC (U.K.), Camurus (Sweden)

Report Scope & Segmentation

Report CoverageDetails
Forecast Period2023 to 2030
Forecast Period 2023 to 2030 CAGR9.1%
2030 Value ProjectionUSD 6.14 billion
Base Year2022
Market Size in 2023USD 3.35 billion
Historical Data2019-2021
No. of Pages129
Segments coveredBy Drug Class, Route of Administration, Distribution Channel, and Region


Browse Complete Report Details: https://www.fortunebusinessinsights.com/opioid-use-disorder-oud-market-102674


Driving factor:

Increasing Cases of Opioid Addiction to Drive the OUD Market Growth

A vast variety of severe and chronic diseases, such as cancer, cardiovascular disease, pain from injuries, and other ailments, affect the general population today. Patients with these disorders frequently have chronic pain, which is generally treated by taking medications, primarily opioids. While the pain diminishes, there is a higher possibility that the patient will become dependent on these drugs. The patient may have withdrawal symptoms as a result of their increasing dependence on these medications and abrupt termination.

Segmentation:

By Drug Class

  • Buprenorphine
  • Methadone
  • Naltrexone

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies & Stores
  • Online Pharmacies

By Region

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • South East Asia

Regional insights:

North America to Hold Lion’s Share Backed by the Presence of Key Players

North America, which had a market value of USD 2.39 billion in 2022, is expected to hold a commanding position during the forecast period due to the significant number of Americans who suffer from opioid dependency, the presence of major players in the region, and the growing involvement of the government in combating the pandemic.

According to projections, Europe will come in second in terms of the global market share. This can be attributed to the region’s increased new product launches as well as rise in patients with opioid dependence.


Quick Buy – https://www.fortunebusinessinsights.com/checkout-page/102674


Competitive Landscape

Acquisitions Initiated by Key Opioid Use Disorder (OUD) Companies to Promote Market Growth

The leading Opioid Use Disorder (OUD) players in the market constantly opt for efficient strategies to bolster their brand value as well as promote global market growth. One such efficient strategy is acquiring competitive companies and further securing a profit for both companies. For instance, in February 2021, Orexo AB collaborated with ApexB.io and Magellan Rx Management for further research use of Modia.


FAQ’s

How big is the opioid use disorder market?
The opioid use disorder market size is USD 3.35 Billion in 2023.

How fast is the opioid use disorder market growing?
The opioid use disorder market will exhibit a CAGR of 9.1% during the forecast period, 2023-2030


Have Any Query? Ask Our Experts:

https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/opioid-use-disorder-oud-market-102674


Related Links:

SUBSTANCE ABUSE TREATMENT Market Size, Share, Growth Industry Report

Drugs Of Abuse Testing Market Share, Size, Demand, and Forecast

Addiction Treatment Market Size, Share, Growth Industry Report

Chronic Lower Back Pain Treatment Market Share, Size, Demand, and Forecast

Parkinson’s Disease Drugs Market Size, Share, Growth Industry Report


About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

Pune – 411045, Maharashtra, India.

Phone:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.